Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:BIIB) revealed 8 unusual trades. Delving into the details, we found 37% of ...
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...
$700,000 of BIOGEN lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Discussions regarding drug pricing and supply ...
Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases.
The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
(RTTNews) - Biogen Inc. (BIIB) announced Thursday that the U.S ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...
Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...
Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (SNSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.